Forteo (teriparatide) plays a unique role in osteoporosis management because it’s one of the few drugs that actually builds new bone rather than simply slowing bone loss. Most osteoporosis medications — bisphosphonates like alendronate, or denosumab — work by putting the brakes on bone resorption. Forteo takes the opposite approach: it stimulates osteoblasts (bone-forming cells) to lay down fresh bone tissue, increasing bone mineral density in a way that anti-resorptive drugs cannot.
This distinction matters enormously for patients with severe osteoporosis or those who’ve already fractured despite being on other treatments. In clinical trials, Forteo reduced new vertebral fractures by 65% and nonvertebral fractures by 53% over a median of 19 months. For the right patient, it can be a game-changer — but it’s not a first-line drug for everyone, and it comes with specific limitations including a maximum 2-year treatment window.
What Exactly Is Forteo?
Forteo is a synthetic version of parathyroid hormone (PTH 1-34) — specifically, the first 34 amino acids of the naturally occurring 84-amino-acid hormone. The FDA approved it in 2002 for:
- Postmenopausal women with osteoporosis at high fracture risk
- Men with primary or hypogonadal osteoporosis at high fracture risk
- Glucocorticoid-induced osteoporosis in patients on sustained systemic corticosteroid therapy
It’s delivered as a once-daily 20 mcg subcutaneous injection, typically into the thigh or abdomen, using a prefilled pen device. Each pen contains a 28-day supply.
How Forteo Builds Bone: The Mechanism
Here’s where the pharmacology gets interesting. Parathyroid hormone, when chronically elevated (as in hyperparathyroidism), actually destroys bone. But when delivered in short, intermittent pulses — like a single daily injection — it paradoxically stimulates bone formation. This is called the anabolic window.
The daily pulse of teriparatide activates osteoblasts before osteoclasts have time to ramp up resorption. The net effect: new bone is deposited on trabecular and cortical surfaces, improving both bone density and bone microarchitecture. This is something anti-resorptive drugs simply cannot do — they preserve existing bone but don’t create new structural connections.
Forteo vs. Other Osteoporosis Drugs
| Feature | Forteo (Teriparatide) | Bisphosphonates (e.g., Alendronate) | Denosumab (Prolia) |
|---|---|---|---|
| Mechanism | Anabolic (builds bone) | Anti-resorptive | Anti-resorptive |
| Route | Daily subcutaneous injection | Oral (weekly or monthly) | Subcutaneous every 6 months |
| Vertebral fracture reduction | 65% | 40–50% | 68% |
| Hip fracture reduction | Not statistically significant in trials | 40–50% | 40% |
| Treatment duration | Max 2 years (lifetime) | 3–5 years, then reassess | Ongoing (rebound risk if stopped) |
| Effect on bone quality | Improves microarchitecture | Increases density, may reduce turnover excessively | Increases density |
| Monthly cost (approx.) | $3,300 (brand); generics now available ~$1,000+ | $10–30 (generic) | ~$1,800 |
Who Should Get Forteo?
Forteo isn’t the starting point for most osteoporosis patients. It’s typically reserved for people with:
- T-scores of -3.0 or lower, especially with prior fractures
- Multiple vertebral compression fractures
- Fractures occurring despite adequate bisphosphonate therapy
- Glucocorticoid-induced osteoporosis (e.g., patients on prednisone ≥5 mg/day for ≥3 months)
- Very high FRAX scores (10-year major osteoporotic fracture probability ≥20% or hip fracture probability ≥3%)
The 2020 Endocrine Society guidelines and the American Association of Clinical Endocrinologists both support using anabolic agents first in very high-risk patients, followed by an anti-resorptive to “lock in” the bone gains. This anabolic-first strategy has become increasingly favored over the older approach of starting with bisphosphonates.
The 2-Year Limit — and What Comes After
Forteo carries a cumulative lifetime limit of 24 months. This restriction dates back to early animal studies where rats given high-dose teriparatide for most of their lifespan developed osteosarcoma (bone cancer). In humans, no causal link has been established after more than two decades of surveillance, but the boxed warning remains.
What matters clinically is what happens after you stop Forteo. Without follow-up anti-resorptive therapy, the bone gains can be lost within 12–18 months. The standard approach is to transition immediately to a bisphosphonate or denosumab to maintain the new bone Forteo built.
Common Side Effects
Most patients tolerate Forteo well, but reported side effects include:
- Orthostatic hypotension — dizziness after the first few doses (patients are advised to sit or lie down for the injection initially)
- Nausea (mild, usually transient)
- Leg cramps
- Hypercalcemia — typically mild; serum calcium should be checked periodically
- Injection site reactions
Forteo is contraindicated in patients with Paget’s disease, unexplained elevated alkaline phosphatase, prior radiation therapy to the skeleton, open epiphyses (children), pre-existing hypercalcemia, or bone metastases.
What About Tymlos (Abaloparatide)?
Abaloparatide (Tymlos), approved in 2017, is a PTH-related peptide analog that works through a similar anabolic mechanism. Head-to-head data from the ACTIVE trial showed comparable vertebral fracture reduction, with abaloparatide demonstrating a statistically significant reduction in nonvertebral fractures versus placebo and potentially less hypercalcemia than teriparatide. Both carry the same 2-year treatment cap. Your doctor may consider either based on cost, availability, and individual risk profile.
Key Takeaways
- Forteo is one of the most powerful tools in osteoporosis management because it builds bone rather than just slowing loss.
- It reduces vertebral fractures by approximately 65% over ~19 months of treatment.
- It’s best suited for patients at very high fracture risk — not mild osteoporosis.
- Treatment is limited to 2 years and must be followed by an anti-resorptive to preserve gains.
- The anabolic-first treatment strategy is now endorsed by major guidelines for the highest-risk patients.
Frequently Asked Questions
How quickly does Forteo increase bone density?
Most patients see measurable BMD improvements within 6–12 months. Lumbar spine density typically increases by 9–13% over 18–24 months, while hip density gains are more modest at around 3–6%. Fracture risk reduction begins even before density changes are fully apparent, likely because Forteo improves bone microarchitecture early on.
Can I take Forteo if I’ve already been on a bisphosphonate?
Yes, but the response may be slightly blunted compared to treatment-naïve patients. Studies show that patients switching from alendronate to teriparatide still gain bone density, though the initial response at the hip may be slower. This is one reason guidelines increasingly recommend starting with Forteo in very high-risk patients rather than switching to it later.
Is the daily injection painful?
The needle is small (similar to an insulin pen), and most patients describe it as a mild pinch. The injection takes about 5 seconds. Some patients report mild burning at the site. After a few weeks, most people say it becomes routine. If needle anxiety is a major barrier, discuss abaloparatide or romosozumab with your doctor as alternative anabolic options.
What happens if I stop Forteo without starting another medication?
Bone density gains reverse relatively quickly — often within 1–2 years. This is well-documented and is the main reason your doctor will recommend transitioning directly to a bisphosphonate or denosumab. Stopping without a follow-up plan essentially wastes the benefit of the treatment course.
Does insurance cover Forteo?
Most insurance plans and Medicare Part D cover Forteo, but typically require prior authorization and documentation of severe osteoporosis or treatment failure on other agents. A generic teriparatide became available in 2023, which has begun to lower costs. The manufacturer also offers a patient savings card that can reduce copays for eligible patients.
